Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 16.09 is 60% above its 5-year average of 10.04, around the middle of its 5-year range (1.18–28.05).
As of the fiscal period ended Tuesday, June 30, 2026. 10.64% above its 12-month average of 14.55.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.09.
CURRENT RATIO
16.09
CURRENT RATIO AVG TTM
14.55
CURRENT RATIO AVG 3Y
5.87
CURRENT RATIO AVG 5Y
10.04
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+10.64%
CURRENT VS 3Y AVG
+174.30%
CURRENT VS 5Y AVG
+60.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.59
median of 798 covered companies
CURRENT VS SECTOR MEDIAN
+347.69%
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$736.18M
Current Ratio
16.09
TTM Avg
14.55
3Y Avg
5.87
5Y Avg
10.04
Market Cap
$738.30M
Current Ratio
19.69
TTM Avg
6.38
3Y Avg
9.16
5Y Avg
11.87
Market Cap
$730.28M
Current Ratio
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$752.29M
Current Ratio
18.86
TTM Avg
23.23
3Y Avg
26.78
5Y Avg
32.61
Market Cap
$727.50M
Current Ratio
14.16
TTM Avg
12.98
3Y Avg
15.39
5Y Avg
17.04
Market Cap
$718.68M
Current Ratio
4.48
TTM Avg
5.45
3Y Avg
6.78
5Y Avg
8.00
Market Cap
$714.67M
Current Ratio
1.03
TTM Avg
1.26
3Y Avg
1.17
5Y Avg
1.16
Market Cap
$763.75M
Current Ratio
2.07
TTM Avg
1.18
3Y Avg
1.89
5Y Avg
3.24
Market Cap
$764.84M
Current Ratio
9.39
TTM Avg
11.79
3Y Avg
11.79
5Y Avg
11.79
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $736.18M | 16.09 | 14.55 | 5.87 | 10.04 |
| Faeth Therapeutics, Inc. (FTH)vs › | $738.30M | 19.69 | 6.38 | 9.16 | 11.87 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $730.28M | 0.95 | 4.92 | 2.98 | 5.72 |
| Design Therapeutics, Inc. (DSGN)vs › | $752.29M | 18.86 | 23.23 | 26.78 | 32.61 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $727.50M | 14.16 | 12.98 | 15.39 | 17.04 |
| Cytek Biosciences, Inc. (CTKB)vs › | $718.68M | 4.48 | 5.45 | 6.78 | 8.00 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $714.67M | 1.03 | 1.26 | 1.17 | 1.16 |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.75M | 2.07 | 1.18 | 1.89 | 3.24 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.84M | 9.39 | 11.79 | 11.79 | 11.79 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $706.51M | 8.86 | 10.22 | 11.35 | 25.38 |
Current Ratio
16.09
Quick Ratio
16.09
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 16.09 |
| 2026-03-31 | 28.05 |
| 2025-12-31 | 13.31 |
| 2025-09-30 | 8.25 |
| 2025-06-30 | 7.04 |
| 2025-03-31 | 4.64 |
| 2024-12-31 | 2.77 |
| 2024-09-30 | 1.18 |
| 2024-06-30 | 1.62 |
| 2024-03-31 | 2.00 |
| 2023-12-31 | 2.59 |
| 2023-09-30 | 4.37 |
| 2023-06-30 | 6.54 |
| 2023-03-31 | 11.82 |
| 2022-12-31 | 12.81 |
| 2022-09-30 | 13.41 |
| 2022-06-30 | 14.86 |
| 2022-03-31 | 17.48 |
| 2021-12-31 | 15.84 |
| 2021-09-30 | 20.68 |
| 2021-06-30 | 5.44 |
| 2021-03-31 | 5.36 |
| 2020-12-31 | 7.46 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
